| Heading: |
Pregnancy: Sodium Valproate |
| Question ID: |
1812896 |
| UIN: |
60056 |
| House: |
Commons |
| Date tabled: |
2025-06-16 |
| Asking Member ID: |
4436 |
| Asking Member display name: |
Cat Smith
|
| Asking Member handle: |
CatSmithMP
|
| Asking Member Twitter reference: |
@CatSmithMP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if (a) he and (b) the Minister for Public Health and Prevention will meet the hon. Member for Lancaster and Wyre to discuss further safety issues to prevent avoidable harm from Sodium Valproate in |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-20 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) is taking proactive steps to inform the public on the very latest safety issues relating to sodium valproate in pregnancy. The MHRA has, most recently in May 2025, approved updated safety and ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |